The Muslim Times has the best collection of articles for the war against Covid 19, especially the vaccines.
Source: CNBC
An analyst at Goldman Sachs thinks a coronavirus vaccine could be approved before year-end by the U.S. as the country tries to stem a massive uptick in cases.
Data compiled by Johns Hopkins University showed U.S. cases grew by a staggering 77,200 — shattering a one-day record. Cases are rising in nearly every state as authorities roll back social distancing measures. California, Florida and Texas are some of the hardest-hit states recently. On Thursday alone, they combined for more than 38,000 cases.
The virus’ rapid spread has led the U.S. government to fast track the development of a potential vaccine, leading Goldman analyst Salveen Richter to believe “a vaccine may gain US approval in 2H20.”
Below are some companies highlighted by Goldman Sachs that could get a vaccine candidate approved later this year.
Moderna
Moderna released data earlier this week that showed all patients in an early trial received neutralizing antibodies after taking the company’s vaccine candidate. The news pushed Moderna shares up more than 40% this week.
“Management guided to potential for full phase 3 efficacy data (151 events) around Thanksgiving (11/26)/4Q20 – however, there are two interim reads at 53 and 106 events – which could enable earlier approval (pursuing a rolling submission; Fast Track designation),” Richter said in a note.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
Novavax starting human trial of its vaccine in Australia
Kaiser Permanente launches first coronavirus vaccine trial
Corona Fear’s Cure: Chanting from the Bible and the Quran
Can You Chant from the Bible or the Quran to Bliss and Happiness?
Japanese flu drug ‘clearly effective’ in treating coronavirus, says China
Synthetic antibodies might offer a quick coronavirus treatment
The Four Possible Timelines for Life Returning to Normal
The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic
Coronavirus: TB Vaccination Trial Started in Melbourne, Australia
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
All of humanity are intimate neighbors: Coronavirus proves it once again
Praise be to God for the Miracle of Our Immune System
USA: 15-minute coronavirus test is here
Does the Ordinary Soap Kill Coronavirus?
Here’s a list of disinfectants you can use against coronavirus
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE
Categories: The Muslim Times, Vaccine
Shares of Moderna (NASDAQ:MRNA) climbed 16% on Friday, following reports that the biotech company is negotiating an advanced purchase deal for its experimental COVID-19 vaccine with the European Union.
Moderna’s stock, which closed at a record high of $94.85, is now up a stunning 385% so far in 2020.
The EU is attempting to line up deals with several coronavirus vaccine makers, according to Reuters. Among these companies are Johnson & Johnson (NYSE:JNJ), Sanofi (NASDAQ:SNY), BioNTech (NASDAQ:BNTX), and Moderna. “We are in talks with several companies on possible COVID-19 vaccines,” an EU spokesperson told Reuters on Friday.
https://www.fool.com/investing/2020/07/17/why-moderna-stock-soared-to-a-new-all-time-high-to.aspx
In addition to its lead in clinical progress, Novavax ranks as the winner so far in securing funding for its COVID-19 vaccine program. The Coalition for Epidemic Preparedness Innovations (CEPI) awarded Novavax up to $388 million for the development and production of NVX-CoV2373. Novavax won a $60 million contract with the U.S. Department of Defense. Most importantly, it’s receiving $1.6 billion in funding from Operation Warp Speed, the U.S. government’s initiative to accelerate the development of COVID-19 vaccine candidates.
Vaxart hasn’t landed such lucrative deals so far. However, its COVID-19 vaccine was selected by Operation Warp Speed to be part of a challenge study in nonhuman primates.
https://www.fool.com/investing/2020/07/18/coronavirus-vaccine-race-novavax-or-vaxart.aspx